No abstract is provided for this article.
The family Flaviviridae contains three genera: Hepacivirus, Flavivirus, and Pestivirus. Worldwide, more than 170 million people are chronically infected with Hepatitis C virus and are at risk of developing cirrhosis and/or liver cancer. In addition, infections with arthropod-borne flaviviruses (such as dengue fever, Japanese encephalitis, tick-borne encephalitis, St. Louis encephalitis, Murray Valley encephalitis, West Nile, and yellow fever viruses) are emerging throughout the world. The pestiviruses have a serious impact on livestock. Unfortunately, no specific antiviral therapy is available for the treatment or the prevention of infections with members of the Flaviviridae. Ongoing research has identified possible targets for inhibition, including binding of the virus to the cell, uptake of the virus into the cell, the internal ribosome entry site of hepaciviruses and pestiviruses, the capping mechanism of flaviviruses, the viral proteases, the viral RNA-dependent RNA polymerase, and the viral helicase. In light of recent developments, the prevalence of infections caused by these viruses, the disease spectrum, and the impact of infections, different strategies that could be pursued to specifically inhibit viral targets and animal models that are available to study the pathogenesis and antiviral strategies are reviewed.
The University of Leuven uses a liquid curtain recoating system for resin deposition in stereolithography. This system deposits new liquid layers of photo-polymer by means of a liquid curtain travelling over the build vat. Experiments have been carried out to increase the speed of the liquid curtain while depositing a layer. Speeds up to 1.2 m/s, and accelerations up to 1 g have been tested successfully, meaning that it is possible to coat high-quality layers of 75 µm thickness with this recoating technique. However, the curtain restores too slowly after acceleration. This paper discusses possible reasons and tries to formulate adequate solutions. Possible solutions consist in controlling small pressure differences in the curtain’s neighbourhood. A solution to this problem is necessary, as to make the travelling length of the curtain, and so the machine length acceptable with respect to the dimensions of the build vat.
Although more and more computer-aided technologies are utilised or demonstrated on well-known monuments or archaeological sites, there is at least for the professionals working in the field still some lack of clarity about their application. The main idea of our research project is to construct a prototype of a tool that tries to bring new technologies closer to the daily practice. It incorporates recent developments in computer vision and reverse engineering, while at the same time tries to answer the practical concerns from civil servants, architects, topographers, art-historians... who are responsible for the conservation of monuments or archaeological sites. The proposed system covers automatic correspondence analysis and point cloud manipulation to build up a textured 3D model. This model then acts as the central core of a multimedia data structure for the annotation, geometric and thematic interrogation and visualisation of the building or site being studied.
Human herpesvirus 6 (HHV-6) is a betaherpesvirus that is closely related to human cytomegalovirus. It was discovered in 1986, and HHV-6 literature has expanded considerably in the past 10 years. We here present an up-to-date and complete overview of the recent developments concerning HHV-6 biological features, clinical associations, and therapeutic approaches. HHV-6 gene expression regulation and gene products have been systematically characterized, and the multiple interactions between HHV-6 and the host immune system have been explored. Moreover, the discovery of the cellular receptor for HHV-6, CD46, has shed a new light on HHV-6 cell tropism. Furthermore, the in vitro interactions between HHV-6 and other viruses, particularly human immunodeficiency virus, and their relevance for the in vivo situation are discussed, as well as the transactivating capacities of several HHV-6 proteins. The insight into the clinical spectrum of HHV-6 is still evolving and, apart from being recognized as a major pathogen in transplant recipients (as exemplified by the rising number of prospective clinical studies), its role in central nervous system disease has become increasingly apparent. Finally, we present an overview of therapeutic options for HHV-6 therapy (including modes of action and resistance mechanisms).
